|Bid||62.26 x 500|
|Ask||62.27 x 300|
|Day's Range||61.95 - 63.24|
|52 Week Range||42.31 - 64.60|
|PE Ratio (TTM)||231.00|
|Earnings Date||Apr 17, 2018 - Apr 23, 2018|
|Forward Dividend & Yield||1.12 (1.77%)|
|1y Target Est||68.22|
Matthew Cheslock joins Yahoo Finance's Seana Smith from the floor of the New York Stock Exchange to discuss the latest moves in the markets.
- National reimbursement adds the device into Japan's health insurance system, which enables greater access for patients - MitraClip is a first-of-its-kind transcatheter mitral valve repair device that ...
A firestorm in cardiology resulted when a major NIH-funded clinical trial changed its design and moved the goalposts just before reaching completion.
On February 27, 2018, Thermo Fisher Scientific (TMO) announced the launch of the new Thermo Scientific Chromeleon XTR Laboratory Management system, which was designed to manage an entire laboratory. The software has the ability to support data integrity, process adherence, and regulatory compliance. The system provides enhanced data software capabilities like sample management and data archiving as compared to the traditional CDS (chromatography data systems).
Do we trade on the news out of Washington? Jim Cramer talks about Larry Kudlow and his stand on economic growth.
ConMed (CNMD) expects to witness the positive impact of around 0.5–1.0 percentage points on its fiscal 2018 adjusted gross margin, attributable to various cost-saving initiatives. ConMed has also projected an improvement of ~0.2–0.5 percentage points in its ratio of SG&A (selling, general, and administrative) expenses to total sales for fiscal 2018 on a YoY (year-over-year) basis. ConMed also expects its 2018 R&D (research and development)-to-sales ratio to be at the higher end of the projected range of 4.5%–5%.
ConMed (CNMD) expects to report revenue growth in the range of 5%–6.5% on a reported basis and in the range of 4.0%–5.0% on a CC (constant currency) basis for fiscal 2018. The company has projected a favorable top-line impact of 100–150 basis points, resulting from foreign exchange movements for fiscal 2018. In 2017, ConMed reported a ~4.3% YoY (year-over-year) rise in revenues on a CC basis, which would be in line with the average revenue growth in the medical technology industry.
Shares in Siemens Healthineers are likely to be priced at 28 euros ($34.64) in its initial public offering, on the lower side of a guidance range of 26 to 31 euros, two sources close the deal said. As a result, Siemens, which will sell a 15 percent stake, is in the frame to reap 4.2 billion euros in proceeds. The shares are set to start trading on the Frankfurt Stock Exchange on Friday.
Headquartered in Utica, New York, ConMed (CNMD) currently employs 3,100 people worldwide. In 4Q17, ConMed reported total sales close to $222.6 million, which represents a YoY (year-over-year) rise of ~7.9% on a CC (constant currency) basis and 9% on a reported basis, driven by the robust uptake of its products in the US and in international geographies. For fiscal 2017, ConMed reported total sales close to $796 million, which represents a YoY rise of ~4.3%, both on a CC and reported basis.
Jim Cramer says if investors want to stick with what's working, then they definitely need to be in tech.
-- HEARTMATE 3™ LVAD DEMONSTRATED IMPROVED CLINICAL OUTCOMES OVER THE MOST WIDELY USED LVAD IN THE WORLD -- MOMENTUM 3 STUDY MET THE PRIMARY ENDPOINT AT TWO YEARS -- RESULTS PRESENTED AT ACC AND SIMULTANEOUSLY ...
On February 26, 2018, Medtronic (MDT) announced that the FDA has approved a new arm indication for its Guardian Sensor 3, the latest and most accurate CGM (continuous glucose monitoring) sensor. The expanded indication will enable the sensor to be worn on the upper arm, thus providing more flexibility, higher accuracy, and enhanced performance. It is the only sensor approved for use with Medtronic’s MiniMed 670G, which is the first HCL (hybrid closed loop) insulin delivery system in the world.
On February 21, 2018, Medtronic (MDT) announced the launch of its MiniMed Mio Advance infusion set, the newest addition to its portfolio of MiniMed infusion sets. The device is used for insulin delivery from an insulin pump to a person’s body. In late 2018, Medtronic plans to expand the commercial availability of the device in other geographies around the world.
The outlook for the US medical products and devices industry has been revised upward, to positive from stable, Moody's Investors Service says in a just-published report. Continued product innovation and ...